Corcept Therapeutics (CORT) AI Stock Analysis

• Market Cap: $7.33B
• Dividend Yield: N/A
• Average Volume (3M): 812.41K
• Price to Earnings (P/E): 61.9
• Beta (1Y): 0.38
• Revenue Growth: 25.71%
• EPS Growth: 4.48%
• Country: US
• Employees: 500
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): 0.29
• Shares Outstanding: 105,371,730
• 10 Day Avg. Volume: 624,905
• 30 Day Avg. Volume: 812,412
• PEG Ratio: 1.15
• Price to Book (P/B): 7.65
• Price to Sales (P/S): 7.71
• P/FCF Ratio: 26.55
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 11.88
• Enterprise Value/Gross Profit: 12.08
• Enterprise Value/Ebitda: 81.93
• 1Y Price Target: $134.50
• Price Target Upside: 93.33% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 73 Outperform
• Price Target: $78.00 ▲(12.12% Upside)

Corcept Therapeutics' strong financial performance and positive corporate events are the primary drivers of its score. However, high valuation metrics and mixed technical indicators moderate the overall outlook. The company's strategic expansions and successful clinical trials provide a positive long-term growth potential.

Positive Factors

Clinical Trials

Positive results from the pivotal ROSELLA study with relacorilant in ovarian cancer give confidence in its potential for a new indication.

Regulatory Progress

An NDA submission for relacorilant in Cushing’s has been accepted for filing by the FDA, indicating strong regulatory progress.

Negative Factors

Legal Uncertainty

The appellate court decision on Korlym IP is expected to be a stock-moving event, which adds uncertainty to the stock.

Supply Chain Issues

Demand continues to outstrip supply for Korlym, and insufficiency at the company's specialty pharmacy vendor has caused revenue to fall short of estimates.

Corcept Therapeutics Business Overview & Revenue Model

Company Description

Corcept Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies that treat serious metabolic and psychiatric disorders by modulating the effects of cortisol, a hormone involved in stress response. The company's lead product, Korlym (mifepristone), is approved for the treatment of Cushing's syndrome, a condition characterized by excessive cortisol levels. Corcept is also engaged in developing additional products aimed at addressing various conditions related to cortisol dysregulation.

How the Company Makes Money

Corcept Therapeutics generates revenue primarily through the sales of Korlym, its approved drug for Cushing's syndrome. The company earns income from product sales to healthcare providers and patients, and it may also receive royalties or milestones from partnerships related to its drug development pipeline. In addition, Corcept has engaged in collaborations with other pharmaceutical companies, which can provide funding and resources for research and development, thereby contributing to its overall revenue. These partnerships may involve sharing in the profits of jointly developed drugs or receiving upfront payments and milestones based on development progress.

Corcept Therapeutics Financial Statement Overview

Summary

Corcept Therapeutics shows strong profitability with high margins and impressive revenue growth, stable financial structure with low leverage, and effective cash flow management, supporting its financial stability in a volatile biotechnology sector.

Income Statement

Corcept Therapeutics demonstrates strong profitability with a Gross Profit Margin consistently above 95% and a solid Net Profit Margin around 18%. The company has shown impressive revenue growth, with a 43% increase from 2022 to 2023 and a smaller yet healthy 6% growth in TTM (Trailing-Twelve-Months). While EBIT and EBITDA margins have slightly declined in the TTM period, they remain robust at approximately 14%.

Balance Sheet

The company maintains a sound financial structure with a Debt-to-Equity Ratio well below 0.02, indicating low leverage. The Equity Ratio is strong, consistently above 75%, reflecting a high level of equity relative to total assets. ROE is healthy at around 21% in the TTM period, though slightly lower compared to previous years, indicating solid return on equity investments.

Cash Flow

Corcept Therapeutics exhibits strong cash flow management. The Operating Cash Flow to Net Income Ratio is consistently above 1, indicating efficient conversion of income to cash. The Free Cash Flow to Net Income Ratio is also robust above 1 in the TTM period. Despite a decrease in Operating Cash Flow compared to 2024, Free Cash Flow remains strong, with a minor decline of 8% in the TTM period, reflecting solid cash flow generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	716.08M	675.04M	482.38M	401.86M	365.98M	353.87M
Gross Profit	704.42M	664.16M	475.89M	396.47M	360.70M	348.29M
EBITDA	103.84M	136.95M	108.32M	113.89M	127.95M	130.44M
Net Income	132.52M	139.73M	106.14M	101.42M	112.51M	106.01M
Balance Sheet
Total Assets	801.72M	840.55M	621.52M	583.43M	423.76M	571.73M
Cash, Cash Equivalents and Short-Term Investments	342.23M	383.33M	368.22M	436.62M	335.81M	476.89M
Total Debt	6.61M	6.94M	151.00K	1.14M	526.00K	2.55M
Total Liabilities	165.93M	160.96M	114.81M	81.59M	47.95M	48.39M
Stockholders Equity	635.79M	679.59M	506.70M	501.84M	375.81M	523.34M
Cash Flow
Free Cash Flow	180.28M	195.90M	126.90M	119.91M	167.42M	150.73M
Operating Cash Flow	182.20M	198.07M	127.04M	120.32M	167.89M	151.97M
Investing Cash Flow	-41.44M	-177.60M	90.91M	-114.33M	136.13M	-119.26M
Financing Cash Flow	-168.39M	-28.35M	-148.72M	-17.28M	-302.59M	12.21M

Corcept Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 69.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Negative. The current price of 69.57 is below the 20-day moving average (MA) of 70.83, below the 50-day MA of 71.04, and above the 200-day MA of 65.54, indicating a neutral trend. The MACD of -0.26 indicates Positive momentum. The RSI at 46.13 is Neutral, neither overbought nor oversold. The STOCH value of 21.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CORT.

Corcept Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	79 Outperform	$8.53B	16.66	179.14%	―	34.97%	71.10%
TECH	75 Outperform	$8.83B	123.47	3.68%	0.57%	5.23%	-56.70%
CORT	73 Outperform	$7.33B	61.91	21.42%	―	25.71%	4.48%
MDGL	56 Neutral	$9.47B	―	-36.30%	―	3421.98%	49.62%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
LEGN	51 Neutral	$6.47B	―	-29.70%	―	75.01%	-13.20%
SRPT	47 Neutral	$1.78B	19.61	-4.76%	―	64.89%	-221.56%

Corcept Therapeutics Corporate Events

Corcept Therapeutics Reports Q2 2025 Financial Results

On July 31, 2025, Corcept Therapeutics announced its financial results for the second quarter of 2025, reporting a revenue increase to $194.4 million from $163.8 million in the same quarter of 2024. Despite a slight decrease in net income, the company highlighted significant clinical development milestones, including the publication of results from its CATALYST and ROSELLA studies and ongoing New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer. Corcept’s advancements in clinical trials and strategic stock repurchases indicate a robust growth trajectory and potential leadership in cortisol modulation therapies.

Corcept Therapeutics Submits New Drug Application to FDA

On July 14, 2025, Corcept Therapeutics announced the submission of a new drug application to the U.S. FDA for relacorilant, a selective cortisol modulator, to treat platinum-resistant ovarian cancer. This submission, based on positive Phase 3 ROSELLA and Phase 2 trial data, marks a significant milestone for Corcept, which now has two NDAs before the FDA. The trials showed that relacorilant, combined with nab-paclitaxel, improved progression-free and overall survival without increasing adverse events compared to nab-paclitaxel alone. The approval of relacorilant could provide a much-needed treatment option for patients with platinum-resistant ovarian cancer, a condition with limited current therapies.

Corcept Therapeutics Holds Annual Stockholder Meeting

On June 10, 2025, Corcept Therapeutics held its annual meeting of stockholders, where key decisions included the election of nine directors, ratification of Ernst & Young LLP as the independent accounting firm for 2025, and approval of executive compensation. These decisions are significant for the company’s governance and operational oversight, impacting its strategic direction and stakeholder relations.